The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A study of neo-adjuvant and adjuvant ofra-vec (VB-111) for treatment of surgically accessible recurrent GBM.
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Andrew J. Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX; Plus Therapeutics
Honoraria - Vascular Biogenics
Consulting or Advisory Role - Alamab Therapeutics; NanoTX; Plus Therapeutics; Vascular Biogenics
Research Funding - Gilead Sciences (Inst); Immunomedics (Inst); Plus Therapeutics (Inst); Upsher-Smith (Inst)
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Nicholas A. Butowski
Stock and Other Ownership Interests - Cordance; Cordance
Consulting or Advisory Role - Cellinta; DelMar Pharmaceuticals; Gan & Lee; Karyopharm Therapeutics; KIYATEC; Lynx Group; Plus Therapeutics; QED Therapeutics; Sagimet Biosciences; Tocagen; VBI Vaccines; VBL Therapeutics
Research Funding - Abbvie (Inst); Amgen; Amgen (Inst); Arbor Pharmaceuticals (Inst); BeiGene (Inst); BeiGene (Inst); BioMimetix (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EpicentRx; Five Prime Therapeutics; Ipsen; Istari (Inst); KIYATEC (Inst); Medicenna; Merck; Oncoceutics (Inst); Orbus Therapeutics; Tocagen (Inst)
 
Tamar Rachmilewitz Minei
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Dror Harats
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research